AstriVax Therapeutics is a clinical stage biopharmaceutical company developing DNA-based immunotherapies using a novel platform technology. This patented technology launches self-amplifying live attenuated viral vectors and antigens to elicit vigorous immune responses. The company focuses on creating these immune interventions to treat challenging chronic diseases, with an initial emphasis on human papillomavirus (HPV).

Confo Therapeutics utilizes a proprietary technology to stabilize functional conformations of G protein-coupled receptors (GPCRs), enabling the identification of previously inaccessible drug targets. The company focuses on developing novel GPCR modulators to provide disease-modifying treatments for patients with severe illnesses that currently lack effective therapies.

Egle Therapeutics develops first-in-class immunotherapies that target regulatory T cells (Tregs) using proprietary IL-2 variants to modulate immune responses in oncology and autoimmune diseases. The company's approach addresses the challenge of immune suppression by selectively disarming tumor-infiltrating Tregs, enabling more effective treatment options for patients.

Epic Therapeutics, Inc. is developing RNA-based therapeutics that target METTL3 methyltransferase, a key enzyme linked to m6A modification, to inhibit tumor growth in acute myeloid leukemia and solid tumors. Their lead candidate, EP102, has demonstrated significant in vivo efficacy, addressing the critical need for effective cancer treatments amid the slow approval of new therapies.

ExeVir develops novel antibody therapies utilizing a modular platform based on camelid antibody fragments (VHH) for infectious disease control. This technology creates stable, cost-effective therapeutic compounds capable of binding multiple conserved epitopes on pathogens. The company is advancing a pipeline focused initially on COVID-19 and dengue to address public health threats, particularly for vulnerable patient populations.

EyeD Pharma develops sustained release micro-implants and complex therapeutics for ophthalmic diseases, targeting conditions such as glaucoma and dry eye. Their solutions aim to enhance patient compliance and minimize treatment side effects, addressing the significant challenge of vision loss affecting over a billion people globally.

Indigo develops the world's first continuous multi-metabolite monitoring (CMM®) system for chronic disease management. This system utilizes a small, implantable sensor based on silicon photonics to continuously measure metabolites like glucose, ketones, and lactate. The data is delivered in real-time to a connected device, providing users and clinicians with actionable insights for improved care.

Minoryx Therapeutics develops leriglitazone, an oral, brain‑penetrant selective PPAR‑γ agonist, to treat X‑linked adrenoleukodystrophy and other orphan central nervous system disorders by restoring mitochondrial function and reducing neuroinflammation. Clinical data from the phase 2/3 ADVANCE trial and pediatric NEXUS study demonstrate slowed cerebral lesion progression and disease stabilization, supporting ongoing phase 3 CALYX and additional neurodegenerative programs.

Ona Therapeutics develops first‑in‑class antibody‑drug conjugates (ADCs) that target novel antigens discovered from the biology of treatment‑refractory advanced cancers. By partnering with academic and clinical researchers, they identify molecular changes in resistant tumors and engineer precision ADCs with optimized pharmacokinetics and payload delivery, advancing only candidates with strong preclinical efficacy and safety.

TargED Biopharmaceuticals develops TGD001, a targeted thrombolytic therapy utilizing small antibodies for localized enzyme delivery to effectively treat various forms of thrombosis. This approach aims to enhance thrombolysis in patients suffering from conditions such as Immune Thrombotic Thrombocytopenic Purpura and Acute Ischemic Stroke, addressing a significant global health issue that contributes to over 16 million deaths annually.